<DOC>
	<DOCNO>NCT02032004</DOCNO>
	<brief_summary>The primary objective study determine whether transendocardial delivery allogeneic human bone marrow-derived MPCs ( rexlemestrocel-L ) effective treatment chronic heart failure due LV systolic dysfunction .</brief_summary>
	<brief_title>Efficacy Safety Allogeneic Mesenchymal Precursor Cells ( Rexlemestrocel-L ) Treatment Heart Failure .</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety single transendocardial delivery cardiac catheterization laboratory human bone marrow-derived allogeneic MPCs ( rexlemestrocel-L ) improvement clinical outcome ( HF-MACE ) , prevent adverse cardiac remodeling ( LVESV LVEDV ) , increase exercise capacity ( 6MWT ) patient chronic HF due LV systolic dysfunction either ischemic nonischemic etiology receive optimal medical/revascularization therapy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>The patient 18 80 year age , inclusive ; men woman enrol . The patient diagnosis chronic HF ischemic nonischemic etiology least 6 month The patient stable , optimally tolerate dosage HF therapy include betablockers ( approve countryspecific usage ) , angiotensinconverting enzyme ( ACE ) inhibitor angiotensinreceptor blocker ( ARBs ) , and/or aldosterone antagonist , without change dose least 1 month study intervention The patient stable , outpatient , oral diuretic dose regimen patient remain clinically stable screening . Other Criteria apply , please contact investigator The patient NYHA Functional Class I Functional Class IV symptom . Other Criteria apply , please contact investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>CHF</keyword>
	<keyword>Left Ventricular Systolic Dysfunction</keyword>
	<keyword>Ischemic Heart Failure</keyword>
	<keyword>Nonischemic Heart Failure</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Allogeneic Mesenchymal Precursor Cells</keyword>
</DOC>